Experienced Life Sciences Executive Joins Leadership Team as Company Further Advances Commercialization of GammaTile
GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer.
“We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies,” said Per Langoe, CEO of GT Medical Technologies. “I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption.”
Health Technology Insights: CGT Global Backs Renown Health’s Breast Cancer Efforts in Nevada
Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management.
“I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors,” said Mr. Leech. “GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company’s continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors.”
Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas.
Health Technology Insights: TransCon hGH Enhances TransCon CNP Results in COACH Trial
Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company’s inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC.
GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment’s effectiveness against remaining cancer cells and reduce the risk of regrowth.
Health Technology Insights: Resonant Clinical Solutions Appoints Christophe Berthoux as Chief Executive Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
